Press

Press September 11 2019


Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Press September 03 2019


Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to prepare NDA filing in Europe

Press June 26 2019


Aus der Forschung: Hoffnung bei Hörsturz?

Press Oktober 18 2018


Strekin AG today Announces the Publication of Key in vivo Data on Mechanisms of STR001 in the Treatment of Sensorineural Hearing Loss

Press September 05 2017


Medikamente gegen das Absterben von Haarzellen im Innenohr

Press May 31 2017


Strekin AG Secures CHF 10 Million Financing for Further Development of STR001 in Sudden Hearing Loss

Press April 11 2017


Strekin’s development candidate, STR001, obtains EU orphan drug designation for the treatment
of Sudden Sensorineural Hearing Loss

Press March 01 2017


Strekin AG Presents Update on Phase 2 Development of STR001 and New Preclinical Data in Hearing Loss

Press 21.10.2016 | 10 vor 10


Sind Hörgeräte bald einmal unnötig?

Press June 30 2016


Strekin AG announces the presentation of key STR001 data at the Conference on Molecular Biology of Hearing and Deafness, Cambridge UK

Press May 17 2016


Strekin AG to develop the P38 MAPK inhibitor Pamapimod

Disclaimer

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued.

Press April 27 2016


Life Science Startup Company Strekin AG announces the launch of a Phase 2 clinical study of STR001 as a potential new treatment for hearing loss

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok